Key result
Persistently high NT-proBNP post-TAVR links to ~470% higher 5-year mortality risk vs. stable low trajectories.
Why the study?
Data on post-TAVR NT-proBNP trends in aortic stenosis are limited, and even fewer reports address the prognostic value of the NT-proBNP trajectory.
Does short-term NT-proBNP trajectory predict 5-year mortality in aortic stenosis patients undergoing TAVR?
Cohort (n=798)
No
Does short-term NT-proBNP trajectory predict 5-year mortality in aortic stenosis patients undergoing TAVR?
Short-term NT-proBNP trajectories following TAVR provide significant prognostic value for 5-year all-cause and cardiac mortality, aiding in risk stratification.
May warrant closer post-TAVR surveillance in high-trajectory patients; leaves open whether trajectory-guided interventions improve outcomes.
Background There are only limited reports on the trends of NT-proBNP after transcatheter aortic valve replacement (TAVR) in aortic stenosis (AS) and even fewer report on the prognostic value of the NT-proBNP trajectory following TAVR. Objectives This study aims to investigate short-term NT-proBNP trajectory following TAVR and explore its association with clinical outcomes in TAVR recipients. Methods Aortic stenosis patients undergoing TAVR were included if they had NT-proBNP levels recorded at baseline, prior to discharge, and within 30 days after TAVR. We used latent class trajectory models to identify NT-proBNP trajectories based on their trends over time. Results Three distinct NT-proBNP trajectories were identified from 798 TAVR recipients, which were named class 1 (N = 661), class 2 (N = 102), and class 3 (N = 35). Compared to those with trajectory class 1, patients with trajectory class 2 had a more than 2.3-fold risk of 5-year all-cause death and 3.4-fold risk of cardiac death, while patients with trajectory class 3 had a more than 6.6-fold risk of all-cause death and 8.8-fold risk of cardiac death. By contrast, the groups had no differences in 5-year hospitalization rates. In multivariable analyses, the risk of 5-year all-cause mortality was significantly higher in patients with trajectory class 2 (HR 1.90, 95% CI 1.03–3.52, P = 0.04) and class 3 (HR 5.70, 95% CI 2.45–13.23, P < 0.01). Conclusion Our findings implied different short-term evolution of NT-proBNP levels in TAVR recipients and its prognostic value for AS patients following TAVR. NT-proBNP trajectory may have further prognostic value, in addition to its baseline level. This may aid clinicians with regards to patient selection and risk prediction in TAVR recipients.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2023) conducted a cohort in Severe aortic stenosis (n=798). Persistently high NT-proBNP trajectory (Class 3) vs. Stable low NT-proBNP trajectory (Class 1) was evaluated on 5-year all-cause mortality (HR 5.70, 95% CI 2.45-13.23, p=<0.01). Patients with severe aortic stenosis and a persistently high NT-proBNP trajectory (class 3) after transcatheter aortic valve replacement had a significantly increased risk of 5-year all-cause mortality (HR 5.70) compared to those with a stable low trajectory.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: